L-NAME HCl Clinical Trials

Size	Price	Qty
100mg	USD 147
1g	USD 370

Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 3 have evaluated L-NAME HCl across conditions including orthostatic hypotension, spinal cord injury, microvascular dysfunction, aging, and pulmonary resistance in tetraplegia. Sponsored by academic institutions—such as the University of Delaware and the Medical College of Wisconsin—and government entities like the US Department of Veterans Affairs, these active, recruiting, and completed studies investigate interventions ranging from post-trauma blood pressure management to nitric oxide pathway modulation in vascular and airway reactivity.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06860724	RECRUITING	Major Depressive Disorder	University of Delaware	2025-01-06
NCT06424756	RECRUITING	Healthy	University of Georgia	2024-07-01	PHASE2
NCT06633198	ACTIVE_NOT_RECRUITING	Aging	William Hughes	2025-05-01	EARLY_PHASE1
NCT06159608	RECRUITING	E-cigarette Use	Anna Stanhewicz, PhD	2023-12-02	EARLY_PHASE1
NCT03684213	COMPLETED	Cardiovascular Diseases; Cardiovascular Risk Factor; Vasoconstriction	The University of Texas at Arlington	2018-10-15	PHASE1
NCT00835224	COMPLETED	Orthostatic Hypotension; Spinal Cord Injury	US Department of Veterans Affairs	2010-05	PHASE2
NCT01002482	COMPLETED	Hyperglycemia; Critical Illness	Centre Hospitalier of Chartres	2009-10	PHASE3
NCT00753948	COMPLETED	Tetraplegia; Asthma	VA Office of Research and Development	2006-12	PHASE2; PHASE3
NCT00237770	COMPLETED	Hypotension; Spinal Cord Injury	US Department of Veterans Affairs	2003-06	PHASE2; PHASE3
NCT00603720	COMPLETED	Cardiovascular Diseases	Washington University School of Medicine	2005-09

(data from https://clinicaltrials.gov, updated on 2025-09-17)

Check the L-NAME HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

L-NAME HCl binds nonselectively to nitric oxide synthase isoforms—including neuronal, endothelial, and inducible variants—thereby blocking the oxidation of L-arginine to nitric oxide and suppressing downstream cyclic GMP signaling. This reduction in endothelial nitric oxide synthesis promotes vascular smooth muscle contraction and restricts vasodilation, providing a mechanistic basis for assessing vascular reactivity, blood pressure elevation, and microvascular function in conditions such as orthostatic hypotension and cardiovascular risk.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).